Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00258310 · OUTCOME

Incidence of Second Primary Tumors

Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo · Source last updated 2023-03-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Within 3 years of end of study

Analysis population: Entire study population

Groups in this outcome

Capecitabine

Capecitabine 1000mg/day for one year capecitabine adjuvant therapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Capecitabine35

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Capecitabine3Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        3
denoms
  1. counts
    1. group Id
      OG000
      value
      35
    units
    Participants
groups
  1. description
    Capecitabine 1000mg/day for one year capecitabine adjuvant therapy
    id
    OG000
    title
    Capecitabine
param Type
COUNT_OF_PARTICIPANTS
population Description
Entire study population
reporting Status
POSTED
time Frame
Within 3 years of end of study
title
Incidence of Second Primary Tumors
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice